At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination With Conventional Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Bone Marrow Aspiration, and 10 other interventions for Acute Myeloid Leukemia and 3 related conditions. Active but no longer recruiting, targeting 49 participants across 10 sites.
Signals
Detailed Summary
This phase II trial studies how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Chemotherapy drugs, such as cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving induction chemotherapy with pembrolizumab may work better than induction chemotherapy alone in treating patients with acute myeloid leukemia.
Study Details
Timeline
Arms & Interventions
See Detailed Description.
See Detailed Description.
Interventions
Undergo collection of blood
Undergo bone marrow aspiration
Undergo bone marrow biopsy
Undergo CT
Given via continuous IV infusion
Given IV
Undergo ECHO
Undergo HSCT
Given IV
Undergo MUGA
Given IV
Undergo a skin punch biopsy